Literature DB >> 8710366

Intracellular expression of a single-chain antibody directed to the EGFR leads to growth inhibition of tumor cells.

C B Jannot1, R R Beerli, S Mason, W J Gullick, N E Hynes.   

Abstract

A gene encoding a single-chain antibody (scFv) which specifically binds the epidermal growth factor receptor (EGFR) has been constructed from hybridoma cells producing the R1 monoclonal antibody. The gene, designated scFv-R1R, was introduced into EGFR transformed NIH3T3 cells via retroviral infection. scFv-R1R was directed to the lumen of the endoplasmic reticulum (ER) where it bound the extracellular domain of the receptor inhibiting its appearance on the plasma membrane. In these cells, EGF induced tyrosine phosphorylation of the EGFR and several substrates was greatly reduced. Furthermore, intracellular retention of EGFR caused a partial inhibition in the transformed growth of the cells. Intracellular expression of receptor tyrosine kinase directed scFvs is a novel approach for affecting tumor cell growth. We have recently shown that scFv-5R directed to ErbB2, another member of the ErbB family, blocks the anchorage independent growth of ErbB2 transformed cells. In order to examine the effects of scFv-R1R and scFv-5R on the long-term growth of tumor cells overexpressing either EGFR or ErbB2, retroviruses encoding the two scFvs were used to infect various human tumor cell lines. Intracellular expression of the scFvs resulted in a marked inhibition of stable colony formation in some of the cell lines. In general, inhibition was observed when overexpressed receptor was targeted. However, in some cases expression of both scFvs was incompatible with long term cell growth suggesting that heterodimers of ErbB2 and EGFR are essential for the growth of some human tumor cell lines.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8710366

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

2.  ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling.

Authors:  D Graus-Porta; R R Beerli; J M Daly; N E Hynes
Journal:  EMBO J       Date:  1997-04-01       Impact factor: 11.598

Review 3.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 4.  The role of the epidermal growth factor receptor in breast cancer.

Authors:  Samuel K Chan; Mark E Hill; William J Gullick
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-01       Impact factor: 2.673

5.  Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.

Authors:  R Asslan; A Pradines; G Favre; F Le Gaillard
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

Review 6.  Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily: role as anticancer agents.

Authors:  S B Noonberg; C C Benz
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

7.  The epidermal growth factor receptor family in breast cancer.

Authors:  Angelos K Koutras; T R Jeffry Evans
Journal:  Onco Targets Ther       Date:  2008-09-01       Impact factor: 4.147

8.  ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.

Authors:  Dmitriy Kedrin; Jeffrey Wyckoff; Pamela J Boimel; Salvatore J Coniglio; Nancy E Hynes; Carlos L Arteaga; Jeffrey E Segall
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

9.  Mass spectrometry based method to increase throughput for kinome analyses using ATP probes.

Authors:  F E McAllister; M Niepel; W Haas; E Huttlin; P K Sorger; S P Gygi
Journal:  Anal Chem       Date:  2013-04-22       Impact factor: 6.986

10.  Aspirin inhibits ErbB2 to induce apoptosis in cervical cancer cells.

Authors:  Shuanglin Xiang; Zhenhua Sun; Qiongzhi He; Feng Yan; Yijun Wang; Jian Zhang
Journal:  Med Oncol       Date:  2009-05-08       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.